About the HTPC

The Consortium is a group of stakeholders currently drawn from the corporate and public interest communities that share the objective of accelerating implementation of biological pathway-based approach to toxicology as described in the National Research Council’s 2007 report on “Toxicity Testing in the 21st Century.”  The paradigm shift described in the NRC report is taking root via several large-scale efforts, primarily in the US and Europe, for example:  Tox21, a US government-sponsored collaboration between the Environmental Protection Agency, Food and Drug Administration, and the National Institute of Environmental Health Sciences, and several Framework Programme projects co-sponsored by the European Commission and industry, including Safety Evaluation Ultimately Replacing Animal Testing (SEURAT).  The Consortium aims to accelerate implementation of methods that result from these and other efforts by providing complementary support in 3 key areas:  1) addressing critical scientific needs not covered by current efforts, 2) communication with stakeholders including non-governmental organizations, government officials and the public, 3) providing an independent venue for lobbying and fundraising to support pathway-based science and policies.

Mission

Serve as a catalyst for the prompt, global, and coordinated implementation of pathway-based toxicology, which will better safeguard human health and hasten the replacement of animal use in toxicology.

Vision

A global paradigm shift to an in vitro approach to the risk assessment of chemicals and drugs that is based on a modern understanding of human biology and disease pathways, yielding results more rapidly and more predictive of human health effects than current approaches.

Current Members of the Consortium

Dow Chemical
DuPont
Exxon Mobil
Hamner Institutes for Health Sciences
HSUS family
– Humane Society of the United States
– Humane Society International
– Humane Society Legislative Fund
The Johns Hopkins Center for Alternatives to Animal Testing (CAAT)
Johnson & Johnson
L’Oreal
Procter & Gamble
Unilever

Key Aims of the Consortium:

  • Technical: Fill gaps and address immediate scientific needs
  • Communication: Promote greater appreciation of the need for a prompt and global transformation to the new paradigm among diverse stakeholders
  • Public policy: Promote the development, adoption and implementation of the new methodology through legislative, appropriations and regulatory advocacy on a global basis
  • Collaboration: Build strategic partnerships to advance the vision of the Consortium, and, where appropriate, expand the Consortium

Comments? Questions? Suggestions?
Contact the consortium coordinator: kwillett at humanesociety dot org